Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

DNA gyrase subunit A

2

DNA topoisomerase IV subunit A

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2014

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acute otitis externa

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

MerLion Pharmaceuticals

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

DRUG BANK

2

EPA CompTox

2

FDA UNII

2

MERCK INDEX

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

FINAFLOXACIN

D26OSN9Q4R

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 2014

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA gyrase subunit A

DNA topoisomerase IV subunit A

Conditions:

Acute otitis externa

Finafloxacin is a fluoroquinolone antimicrobial agent that exhibits optimum efficacy in slightly acidic environments and is a highly potent eradicator of Helicobacter pylori. Being developed to treat serious bacterial infections associated with an ac...

idic environment, including urinary tract infections and Helicobacter pylori infections finafloxacin is approved for treatment of acute otitis externa (swimmer’s ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. XTORO (finafloxacin otic suspension), 0.3% is supplied as a sterile, preserved, aqueous suspension. Finafloxacin is a drug with a favorable safety profile.

FINAFLOXACIN HYDROCHLORIDE

2G22PNZ052

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 2014

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA gyrase subunit A

DNA topoisomerase IV subunit A

Conditions:

Acute otitis externa

Finafloxacin is a fluoroquinolone antimicrobial agent that exhibits optimum efficacy in slightly acidic environments and is a highly potent eradicator of Helicobacter pylori. Being developed to treat serious bacterial infections associated with an ac...

idic environment, including urinary tract infections and Helicobacter pylori infections finafloxacin is approved for treatment of acute otitis externa (swimmer’s ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. XTORO (finafloxacin otic suspension), 0.3% is supplied as a sterile, preserved, aqueous suspension. Finafloxacin is a drug with a favorable safety profile.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1